Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents

Clinical and Translational Oncology

Volumn 9, Issue 3, 2007, Pages 161-171

  Camps, C ^a   Juarez A ^a   Iranzo, V ^a   Garde, J ^a   Blasco, A ^a   Sirera, R ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Anticoagulant agents; Cancer; Central venous catheterisation; Chemotherapy; Deep venous thrombosis; Hospitalisation; Low molecular weight heparin; Pulmonary embolism; Surgery

Indexed keywords

ACENOCOUMAROL; ANASTROZOLE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BETA THROMBOGLOBULIN; CYTOTOXIC AGENT; D DIMER; DALTEPARIN; ENOXAPARIN; FIBRIN; FIBRINOPEPTIDE B; FLUOROURACIL; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; THALIDOMIDE; THROMBIN ANTITHROMBIN COMPLEX; TINZAPARIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN INHIBITOR; WARFARIN; XIMELAGATRAN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; FIBRINOLYTIC AGENT; PEPTIDE HYDROLASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURGERY; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LUNG CARCINOMA; LUNG EMBOLISM; MONOTHERAPY; NEOPLASM; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SURVIVAL RATE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLOOD; CENTRAL VENOUS CATHETERIZATION; CHEMICALLY INDUCED DISORDER; DOUBLE BLIND PROCEDURE; FEMALE; IMMOBILIZATION; MALE; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RISK; STATISTICS; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTITHROMBIN III; CATHETERIZATION, CENTRAL VENOUS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMOBILIZATION; MALE; NEOPLASMS; PEPTIDE HYDROLASES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK; THROMBOEMBOLISM; THROMBOPHILIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOSIS;

EID: 34250351970     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0030-7     Document Type: Review

References (123)

1. Klerk CP, Smorenburg SM, Otten HM et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135
2. Hansson PO, Welin L, Tibblin G, Eriksson H (1997). Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Intern Med 157: 1665-1670
3. Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 87:575-579
4. Heit JA, Mohr DN, Silverstein MD et al (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A populationbased cohort study. Arch Intern Med 160:761-768
5. Lee AY (2003) Anti-thrombotic therapy in cancer patients. Exp Opin Pharmacother 4:2213-2220
6. Levitan N, Dowlati A, Remick SC et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78: 285-291
7. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343: 1846-1850
8. White RH, Chew HK, Zhou H et al (2005) Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 165:1782-1787
9. Levine MN, Gent M, Hirsh J et al (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404-407
10. Saphner T, Tormey DC, Gray R (1991) Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9:286-294
11. Rosendaal FR (1997) Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol 34:171-187
12. Bona RD, Hickey AD, Wallace DM (2000) Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol 23:71-73
13. Hutten BA, Prins MH, Gent M et al (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 18:3078-3083
14. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488
15. Heit JA, Silverstein MD, Mohr DN et al (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study. Arch Intern Med 159:445-453
16. Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7
17. Holzheimer RG (2004) Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). Eur J Med Res 9:150-170
18. Kakkar AK, Levine M, Pinedo HM et al (2003) Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. Oncologist 8:381-388
19. Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:401S-428S
20. Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S-400S
21. Ottani F, Galvani M (2001) Prognostic role of hemostatic markers in acute coronary syndromes patients. Clin Chim Acta 311:33-39
22. Seitz R, Blanke H, Pratorius G et al (1988) Increased thrombin activity during thrombolysis. Thromb Haemost 59:541-542
23. Koehn JA, Canfield RE (1981) Purification of human fibrinopeptides by high-performance liquid chromatography. Anal Biochem 116:349-356
24. Lee LV, Ewald GA, McKenzie CR, Eisenberg PR (1997) The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 17:628-633
25. Takada A, Shizume K, Ozawa T et al (1986) Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 42: 63-72
26. Ridker PM, Vaughan DE, Stampfer MJ et al (1993) Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165-1168
27. Montes R, Paramo JA, Angles-Cano E, Rocha E (1996) Development and clinical application of a new ELISA assay to determine plasmin-alpha2- antiplasmin complexes in plasma. Br J Haematol 92:979-985
28. Nenci GG, Berrettini M, Todisco T, Parise P (1981) Enhanced plasma beta-thromboglobulin in hypoxemia: Effect of dipyridamole. N Engl J Med 304:1044
29. Bernstein R, Haim N, Brenner B et al (2004) Venous sonography for the diagnosis of asymptomatic deep vein thrombosis in patients with cancer undergoing chemotherapy. J Ultrasound Med 23:655-658
30. Di Nisio M, Rutjes AW, Buller HR (2006) Combined use of clinical pretest probability and Ddimer test in cancer patients with clinically suspected deep venous thrombosis. J Thromb Haemost 4:52-57
31. Hunt BJ (2006) Plasma D-dimer assays in the diagnosis of venous thromboembolism in cancer patients. J Thromb Haemost 4:50-51
32. Guadagni F, Ferroni P, Basili S et al (2004) Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients. Lung Cancer 44:303-310
33. Falanga A, Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 25:173-182
34. Seitz R, Rappe N, Kraus M et al (1993) Activation of coagulation and fibrinolysis in patients with lung cancer: Relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 4:249-254
35. Kakkar AK, Lemoine NR, Scully MF et al (1995) Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82:1101-1104
36. Shoji M, Hancock WW, Abe K et al (1998) Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 152:399-411
37. Verheul HM, Hoekman K, Lupu F et al (2000) Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 6:166-171
38. Unsal E, Atalay F, Atikcan S, Yilmaz A (2004) Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 98:93-98
39. Buccheri G, Ferrigno D, Ginardi C, Zuliani C (1997) Haemostatic abnormalities in lung cancer: Prognostic implications. Eur J Cancer 33:50-55
40. Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745-749
41. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410
42. Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83-90
43. Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143-158
44. Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5:436-446
45. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435
46. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
47. Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712
48. Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705
49. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
50. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall- cell lung cancer. J Clin Oncol 22:2184-2191
51. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676
52. Lee JH, Canny MD, De Erkenez A et al (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 102:18902-18907
53. Pellegrini L (2001) Role of heparan sulfate in fibroblast growth factor signalling: A structural view. Curr Opin Struct Biol 11:629-634
54. Hori A, Sasada R, Matsutani E et al (1991) Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51: 6180-6184
55. Vlodavsky I, Miao HQ, Medalion B et al (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15:177-186
56. Hettiarachchi RJ, Smorenburg SM, Ginsberg J et al (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82:947-952
57. Lee AY, Rickles FR, Julian JA et al (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129
58. Heit JA, O'Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med 162:1245-1248
59. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948
60. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: Risks and outcomes. Circulation 107:I17-21
61. Fisher B, Dignam J, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682
62. Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484
63. Levine M, Hirsh J, Gent M et al (1994) Doubleblind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889
64. Pritchard KI, Paterson AH, Paul NA et al (1996) Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14:2731-2737
65. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139
66. Minnema MC, Breitkreutz I, Auwerda JJ et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18:2044-2046
67. Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715-721
68. Kakkar AK, Williamson RC (1999) Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 25:239-243
69. Bergqvist D (2001) Venous thromboembolism and cancer: Prevention of VTE. Thromb Res 102:V209-213
70. Clagett GP, Reisch JS (1988) Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 208: 227-240
71. Gallus AS (1990) Anticoagulants in the prevention of venous thromboembolism. Baillieres Clin Haematol 3:651-684
72. Bergqvist D, Burmark US, Flordal PA et al (1995) Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 82:496-501
73. Clark-Pearson DL, DeLong E, Synan IS et al (1990) A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 75: 684-689
74. Clarke-Pearson DL, Coleman RE, Synan IS et al (1983) Venous thromboembolism prophylaxis in gynecologic oncology: A prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 145:606-613
75. Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975-980
76. Rasmussen MS, Willie-Jorgensen P, Jorgensen LN et al (2003) Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy [abstract]. Blood 102:56a
77. Walshe LJ, Malak SF, Eagan J, Sepkowitz KA (2002) Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 20:3276-3281
78. Bern MM, Lokich JJ, Wallach SR et al (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112:423-428
79. Monreal M, Alastrue A, Rull M et al (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75:251-253
80. Verso M, Agnelli G, Bertoglio S et al (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23:4057-4062
81. Couban S, Goodyear M, Burnell M et al (2005) Randomized placebo-controlled study of lowdose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23:4063-4069
82. Karthaus M, Kretzschmar A, Kroning H et al (2006) Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: Final results of a doubleblind, placebo-controlled phase III trial. Ann Oncol 17:289-296
83. Lee AY, Levine MN, Butler G et al (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24:1404-1408
84. Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341:793-800
85. Dahan R, Houlbert D, Caulin C et al (1986) Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 16:159-164
86. Leizorovicz A, Cohen AT, Turpie AG et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874-879
87. Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484-490
88. Mismetti P, Laporte-Simitsidis S, Tardy B et al (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or lowmolecular- weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost 83:14-19
89. Wade WE, Chisholm MA (1999) Cost-effectiveness analysis of deep vein thrombosis prophylaxis in internal medicine patients. Thromb Res 94:65-68
90. Lamy A, Wang X, Kent R et al (2002) Economic evaluation of the MEDENOX trial: A Canadian perspective. Medical Patients with Enoxaparin. Can Respir J 9:169-177
91. Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1:1309-1312
92. Kernohan RJ, Todd C (1966) Heparin therapy in thromboembolic disease. Lancet 1:621-623
93. Alpert JS, Smith R, Carlson J et al (1976) Mortality in patients treated for pulmonary embolism. JAMA 236:1477-1480
94. Kanis JA (1974) Heparin in the treatment of pulmonary thromboembolism. Thromb Diath Haemorrh 32:519-527
95. Siguret V, Pautas E, Fevrier M et al (2000) Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84:800-804
96. Salzman EW, Deykin D, Shapiro RM, Rosenberg R (1975) Management of heparin therapy: Controlled prospective trial. N Engl J Med 292: 1046-1050
97. Glazier RL, Crowell EB (1976) Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 236:1365-1367
98. Hommes DW, Bura A, Mazzolai L et al (1992) Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 116:279-284
99. Dolovich LR, Ginsberg JS, Douketis JD et al (2000) A meta-analysis comparing low-molecular- weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160:181-188
100. Levine M, Gent M, Hirsh J et al (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677-681
101. Koopman MM, Prandoni P, Piovella F et al (1996) Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334:682-687
102. (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 337:657-662
103. Lagerstedt CI, Olsson CG, Fagher BO et al (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2:515-518
104. Hull R, Delmore T, Genton E et al (1979) Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 301:855-858
105. Levine MN, Hirsh J, Gent M et al (1995) Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74:606-611
106. Schulman S, Rhedin AS, Lindmarker P et al (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332:1661-1665
107. Levine MN (2002) Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 28:145-149
108. Lee AY (2001) Treatment of venous thromboembolism in cancer patients. Thromb Res 102: V195-208
109. Iorio A, Guercini F, Pini M (2003) Low-molecular- weight heparin for the long-term treatment of symptomatic venous thromboembolism: Metaanalysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 1: 1906-1913
110. Gitter MJ, Jaeger TM, Petterson TM et al (1995) Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 70:725-733
111. Lee AY, Levine MN, Baker RI et al (2003) Lowmolecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153
112. Hull R, Pineo GF, Mah A (2003) A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer [abstract]. Thromb Haemost P137a
113. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 162:1729-1735
114. Schulman S, Lindmarker P (2000) Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342:1953-1958
115. Altinbas M, Coskun HS, Er O et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecularweight heparin in small cell lung cancer. J Thromb Haemost 2:1266-1271
116. Miller GJ, Bauer KA, Howarth DJ et al (2004) Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2:2107-2114
117. Fiessinger JN, Huisman MV, Davidson BL et al (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. JAMA 293:681-689
118. Buller HR, Davidson BL, Decousus H et al (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702
119. Buller HR, Davidson BL, Decousus H et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 140:867-873
120. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688-698
121. Warkentin TE, Levine MN, Hirsh J et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332: 1330-1335
122. Masci G, Magagnoli M, Zucali PA et al (2003) Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21:736-739
123. Kovacs MJ, Levine MN, Keeney M et al (2005) Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thromb Haemost 93:1185-1188